MTANZ board member Aisling Weir explores the history and complexities of medical device regulation in New Zealand. She discusses the challenges and opportunities within the evolving landscape of medical technology and how new legislation - the Medical Products Bill - aims to address these issues. Also, the difficulty of regulating AI in relation to medical devices and what New Zealand could learn from how international regulatory agencies are approaching this.
All content for eHealthTALK NZ is the property of Rebecca McBeth and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
MTANZ board member Aisling Weir explores the history and complexities of medical device regulation in New Zealand. She discusses the challenges and opportunities within the evolving landscape of medical technology and how new legislation - the Medical Products Bill - aims to address these issues. Also, the difficulty of regulating AI in relation to medical devices and what New Zealand could learn from how international regulatory agencies are approaching this.
MTANZ board member Aisling Weir explores the history and complexities of medical device regulation in New Zealand. She discusses the challenges and opportunities within the evolving landscape of medical technology and how new legislation - the Medical Products Bill - aims to address these issues. Also, the difficulty of regulating AI in relation to medical devices and what New Zealand could learn from how international regulatory agencies are approaching this.
eHealthTALK NZ
MTANZ board member Aisling Weir explores the history and complexities of medical device regulation in New Zealand. She discusses the challenges and opportunities within the evolving landscape of medical technology and how new legislation - the Medical Products Bill - aims to address these issues. Also, the difficulty of regulating AI in relation to medical devices and what New Zealand could learn from how international regulatory agencies are approaching this.
